HUE062453T2 - Rákbetegség kezelése - Google Patents

Rákbetegség kezelése

Info

Publication number: HUE062453T2
Authority: HU; Hungary
Prior art keywords: cancer treatment; cancer; treatment
Prior art date: 2017-02-06

Application number

HUE18702299A

Other languages

English (en)

Inventor

Kim Stuyckens

Ruixo Juan Perez

Porre Peter De

Anjali Avadhani

Yohann Loriot

Arlene Siefker-Radtke

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-06

Filing date

2018-02-02

Publication date

2023-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE062453(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-02-02 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2023-11-28 Publication of HUE062453T2 publication Critical patent/HUE062453T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N33/575—
- G01N33/57585—

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Plural Heterocyclic Compounds (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Prostheses (AREA)
Medicinal Preparation (AREA)
Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
Laminated Bodies (AREA)

HUE18702299A 2017-02-06 2018-02-02 Rákbetegség kezelése HUE062453T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762455211P	2017-02-06	2017-02-06
EP17209098		2017-12-20

Publications (1)

Publication Number	Publication Date
HUE062453T2 true HUE062453T2 (hu)	2023-11-28

Family

ID=61094531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE18702299A HUE062453T2 (hu)	2017-02-06	2018-02-02	Rákbetegség kezelése

Country Status (26)

Country	Link
US (2)	US11077106B2 (hu)
EP (2)	EP3576740B1 (hu)
JP (3)	JP2020505425A (hu)
KR (2)	KR20250069693A (hu)
CN (1)	CN110198716A (hu)
AU (2)	AU2018216969B2 (hu)
BR (1)	BR112019016043A2 (hu)
CA (1)	CA3049737A1 (hu)
DK (1)	DK3576740T3 (hu)
ES (1)	ES2953005T3 (hu)
FI (1)	FI3576740T3 (hu)
HR (1)	HRP20230697T1 (hu)
HU (1)	HUE062453T2 (hu)
IL (1)	IL268463A (hu)
JO (1)	JOP20190190A1 (hu)
LT (1)	LT3576740T (hu)
MX (2)	MX2019009304A (hu)
NZ (2)	NZ796822A (hu)
PH (1)	PH12019501885A1 (hu)
PL (1)	PL3576740T3 (hu)
RS (1)	RS64778B1 (hu)
SG (2)	SG11201907199QA (hu)
SI (1)	SI3576740T1 (hu)
SM (1)	SMT202300233T1 (hu)
TW (1)	TWI874925B (hu)
UA (1)	UA126336C2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA037920B1 (ru)	2014-09-26	2021-06-07	Янссен Фармацевтика Нв	Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
US20200208224A1 (en) *	2014-09-26	2020-07-02	Janssen Pharmaceutica Nv	Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) *	2017-02-06	2019-08-04	Janssen Pharmaceutica Nv	معالجة سرطان
WO2020165181A1 (en) *	2019-02-12	2020-08-20	Janssen Pharmaceutica Nv	Cancer treatment
EP4548935A3 (en) *	2019-03-29	2025-08-06	JANSSEN Pharmaceutica NV	Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP7747521B2 (ja) *	2019-03-29	2025-10-01	ヤンセンファーマシューティカエヌ．ベー．	尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JOP20220182A1 (ar) *	2020-02-12	2023-01-30	Janssen Pharmaceutica Nv	مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2021201201A1 (ja) *	2020-04-03	2021-10-07	インタープロテイン株式会社	新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) *	2023-05-24	2025-03-01	比利時商健生藥品公司	癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20200201A1 (ar) *	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) *	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) *	2017-02-06	2019-08-04	Janssen Pharmaceutica Nv	معالجة سرطان

2017
- 2017-06-16 JO JOP/2019/0190A patent/JOP20190190A1/ar unknown
2018
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 NZ NZ796822A patent/NZ796822A/en unknown
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 NZ NZ755301A patent/NZ755301A/en unknown
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871A1/en active Pending
- 2024-11-11 JP JP2024196985A patent/JP2025024064A/ja active Pending

Also Published As

Publication number	Publication date
LT3576740T (lt)	2023-08-10
ES2953005T3 (es)	2023-11-07
SI3576740T1 (sl)	2023-10-30
UA126336C2 (uk)	2022-09-21
MX2019009304A (es)	2019-09-19
MX2022007955A (es)	2022-07-27
TWI874925B (zh)	2025-03-01
JP2025024064A (ja)	2025-02-19
JOP20190190A1 (ar)	2019-08-04
NZ796822A (en)	2025-12-19
SG10202105110VA (en)	2021-06-29
NZ755301A (en)	2025-12-19
BR112019016043A2 (pt)	2020-03-31
KR20250069693A (ko)	2025-05-19
TW202402290A (zh)	2024-01-16
EP4286005A3 (en)	2024-03-06
AU2018216969A1 (en)	2019-07-25
HRP20230697T1 (hr)	2023-10-13
PH12019501885A1 (en)	2020-06-29
CA3049737A1 (en)	2018-08-09
US20220110935A1 (en)	2022-04-14
EP4286005A2 (en)	2023-12-06
KR20190110581A (ko)	2019-09-30
IL268463A (en)	2019-09-26
JP2020505425A (ja)	2020-02-20
SG11201907199QA (en)	2019-09-27
RS64778B1 (sr)	2023-11-30
US11077106B2 (en)	2021-08-03
AU2024201871A1 (en)	2024-04-11
PL3576740T3 (pl)	2023-09-11
JP2023022190A (ja)	2023-02-14
CN110198716A (zh)	2019-09-03
EP3576740A1 (en)	2019-12-11
EP3576740B1 (en)	2023-06-14
JP7668777B2 (ja)	2025-04-25
SMT202300233T1 (it)	2023-09-06
AU2018216969B2 (en)	2024-04-11
FI3576740T3 (fi)	2023-08-31
DK3576740T3 (da)	2023-07-24
US20200022976A1 (en)	2020-01-23

Publication	Publication Date	Title
IL271946A (en)	2020-02-27	Combination for cancer treatment
ZA201905902B (en)	2021-05-26	2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PT3576740T (pt)	2023-08-18	Tratamento de cancro
IL263123A (en)	2018-12-31	Cancer treatments
IL259996A (en)	2018-07-31	Combinations for cancer treatment
IL268463A (en)	2019-09-26	Cancer treatment
GB201706451D0 (en)	2017-06-07	Cancer treatment
IL247859A0 (en)	2016-11-30	Cancer treatment
IL274626A (en)	2020-06-30	Cancer treatment
ZA201707024B (en)	2019-02-27	Cancer treatment composition
IL260814A (en)	2018-10-31	Cancer treatment
GB201707864D0 (en)	2017-06-28	Platinum-reistant cancer treatment
IL274748A (en)	2020-07-30	Improved cancer treatment
GB201522433D0 (en)	2016-02-03	Cancer treatment
GB201519734D0 (en)	2015-12-23	Cancer therapy
GB201718985D0 (en)	2018-01-03	Treatment
GB201704909D0 (en)	2017-05-10	Cancer therapy
GB201819920D0 (en)	2019-01-23	Cancer treatment
GB201711855D0 (en)	2017-09-06	Cancer therapy
GB201713852D0 (en)	2017-10-11	Cancer treatment
GB201811431D0 (en)	2018-08-29	Cancer treatment
GB201804816D0 (en)	2018-05-09	Cancer treatment
GB201720533D0 (en)	2018-01-24	Cancer treatments
GB201711250D0 (en)	2017-08-30	Cancer therapy
GB201710198D0 (en)	2017-08-09	Cancer therapy